From the *Hubert Department of Global Health
†Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia
‡Emory Vaccine Center, Atlanta, Georgia
§Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, Georgia
¶Centre pour le Développement des Vaccins, Bamako, Mali
‖Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
**Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa
††Department of Science and Technology, Vaccine-Preventable Diseases Section, National Research Foundation, Johannesburg, South Africa
‡‡Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
§§Cincinnati Children’s Hospital Global Health Center, Cincinnati, Ohio
¶¶National Institute for Communicable Diseases, The National Health Laboratory Service, Centre for Vaccines and Immunology, Johannesburg, South Africa
‖‖Bill & Melinda Gates Foundation, Seattle, Washington.
Accepted for publication January 3, 2018.
The 3 trials were registered with ClinicalTrials.gov (registration numbers NCT01430689, NCT01034254 and NCT02465190, respectively).
The authors have no funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Saad B. Omer, MB BS, MPH, PhD, Hubert Department of Global Health, CNR 7017, Rollins School of Public Health, Emory University, 1518 Clifton Rd NE, Atlanta, GA 30322. E-mail: [email protected]
